RCC, HCC and thyroid cancer have been approved for treatment with VEGFR2 TKIs such as sunitinib (RCC), sorafenib (RCC, HCC), pazopanib (RCC), axitinib (RCC) or vandetanib (MTC). Here, KDR is linked to medullary thyroid gland carcinoma.